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Abstract: During the last decade, the risk of venous thromboembolism (VTE) has been reported 
in users of antipsychotic drugs. However, the reports have been inconclusive. This study aimed to 
determine the relative risk of VTE in antipsychotic drug users. Using data from medical databases 
in North Jutland and Aarhus Counties, Denmark, and the Danish Civil Registration System, we 
identiﬁ  ed 5,999 cases with a ﬁ  rst-time diagnosis of VTE and, based on risk set sampling, 59,990 
sex- and age-matched population controls during 1997–2005. Users of antipsychotic drugs 
were identiﬁ  ed from population-based prescription databases and categorized based on ﬁ  lled 
prescriptions prior to admission date for VTE or index date for controls as current (at least one 
prescription within 90 days), recent (at least one prescription within 91–180 days), former (at least 
one prescription within 181–365 days) or nonusers (no recorded prescription within 365 days). 
Compared with nonusers, current users of any antipsychotic drugs had an increased risk of VTE 
(adjusted relative risk [ARR]: 1.99, 95% conﬁ  dence interval [CI]: 1.69–2.34). Former users 
of any antipsychotic drugs had a nonsigniﬁ  cant elevated risk of VTE compared with nonusers 
(ARR: 1.54, 95% CI: 0.99–2.40, p-value: 0.056). In conclusion, users of antipsychotic drugs 
have an increased risk of VTE, compared with nonusers, which might be due to the treatment 
itself, to lifestyle factors, to the underlying disease, or to residual confounding.
Keywords: antipsychotic agents, venous thromboembolism, adverse effects, case-control 
study
Introduction
Schizophrenia is a chronic, severe, and disabling disorder with a lifetime prevalence 
of about 0.5% in the general population.1 Patients suffering from schizophrenia and 
other psychotic disorders have increased morbidity and mortality from cardiovascular 
disease.2 During the past decade, several studies3–12 have reported that treatment with 
antipsychotic drugs also may be associated with an increased risk of venous thrombo-
embolism (VTE). The hypothesized association between ﬁ  rst-generation (conventional) 
antipsychotic drugs and VTE is based primarily on one case-control study3 where 
Zornberg and colleagues observed a risk of VTE for patients aged less than 60 years 
currently treated with ﬁ  rst-generation antipsychotics, compared with former users of 
these drugs. As only a limited number of study subjects were taking second-generation 
(atypical) antipsychotics, the risk of VTE in patients using these newer drugs could 
not be evaluated in that study. The suggested association between second-generation 
antipsychotics and VTE is primarily supported by a cohort study4 of nursing home 
residents aged 65 years or older where a risk of VTE was observed in new users of 
second-generation antipsychotics, compared to nonusers. However, in that study no 
increased risk of VTE in users of ﬁ  rst-generation antipsychotics was found. Ray and 
colleagues12 did not ﬁ  nd an association with VTE in a cohort of patients 65 years of age 
or older treated with any antipsychotic drug, except for patients receiving haloperidol, Clinical Epidemiology 2009:1 20
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compared to users of thyroid hormones. Available data on 
the association between antipsychotic drug use and VTE thus 
remains conﬂ  icting. We undertook this population-based 
study to investigate the hypothesized increased risk of 
VTE in current, recent and former users of ﬁ  rst-generation 
(low-potency and high-potency) and second-generation 
antipsychotic drugs.
Methods
This population-based case-control study was conducted 
within the counties of Aarhus and North Jutland, Denmark, 
from January 1, 1997 to December 31, 2005. The two coun-
ties have a combined population of 1.1 million, representing 
approximately 20% of the Danish population. In Denmark 
use of civil registration numbers (permanent unique identi-
ﬁ  ers provided at birth to each Danish citizen) allows unam-
biguous linkage between all demographic and healthcare 
registries.13
Hospital registries contain records of discharges from 
all nonpsychiatric hospitals since 197713 and since 1995 
for all outpatient visits. Their ﬁ  les include civil registration 
number, dates of hospital admission and discharge, and up 
to 20 discharge diagnoses and procedures, coded according to 
the international classiﬁ  cation of diseases, 8th revision (ICD-8) 
until the end of 1993 and 10th revision (ICD-10) thereafter. The 
Danish National Health Service provides tax-supported health 
care for all residents of Denmark, including partial reimburse-
ment of the cost of prescribed medications.13 The pharmacies 
serving Aarhus and North Jutland counties employ electronic 
accounting systems, used primarily to secure reimbursement 
from the National Health Service. For each ﬁ  lled prescription 
of reimbursed drugs, data on the customer’s civil registration 
number, type and amount of drug prescribed according to 
the Anatomical Therapeutic Chemical (ATC) classiﬁ  cation 
system, and date of dispensing are transferred from the phar-
macies to prescription databases established in 1989 in North 
Jutland County and in 1996 in Aarhus County.
We used the hospital registries to identify all patients with 
a ﬁ  rst-time diagnosis of VTE, ie, deep vein thrombosis in a 
lower limb (ICD-8 code: 451.00 and ICD-10 codes: I80.1, 
180.2, 180.3) and/or pulmonary embolism (ICD-8 code: 
450.99 and ICD-10 code: 126). To control for the increased 
risk of VTE observed in immobilized patients,14 we excluded 
patients with VTE as a secondary admission diagnosis. In 
a second analysis only patients with a primary idiopathic 
VTE were included and patients with a secondary VTE,15 
ie, with well-established predisposing conditions deﬁ  ned as 
surgery, major trauma, fractures, pregnancy within the prior 
three months, pre-existing cancer, or a cancer diagnosis within 
the three months following VTE diagnosis14 were excluded.
Using the Civil Registration System, which has recorded 
data on vital status, address, and emigration status for the 
Danish population since April 1, 1968,13 we identified 
10 population controls for each VTE case, matched on age, 
sex and county. The controls were selected using risk set 
sampling and assigned an index date identical to the VTE 
admission date for the matched case.
For both cases and controls, we extracted data from 
the hospital registries on myocardial infarction, stroke, 
chronic obstructive pulmonary disease (COPD), peripheral 
atherosclerosis in the legs, heart failure and diabetes mellitus 
from the hospital registries, since all these diseases might 
increase the risk of VTE.16–18 We included only diagnoses 
recorded before the hospital admission date for VTE or the 
index date for controls.
From the population-based prescription databases of 
North Jutland and Aarhus Counties, we obtained data on all 
prescriptions for antipsychotic drugs ﬁ  lled within 365 days 
before the VTE-related hospital admission date for cases 
or the index date for controls. The drugs were classiﬁ  ed as 
ﬁ  rst-generation low-potency antipsychotics (chlorpromazine, 
chlorprotixene, melperone, pipamperone, promazine and 
thioridazine), ﬁ  rst-generation high-potency antipsychotics 
(ﬂ  uphenazine, ﬂ  upenthixol, haloperidol, penﬂ  uridol, peri-
ciazine, perphenazine, pimozide, and zuclopenthixol) and 
second-generation antipsychotics (amisulpride, clozapine, 
olanzapine, quetiapine, risperidone, sertindole, sulpiride, 
and ziprasidone).
Current users of antipsychotic drugs were deﬁ  ned as 
having ﬁ  lled at least one prescription for any antipsychotic 
drugs within 90 days before their hospital admission date for 
VTE or index date for controls. Recent users were deﬁ  ned as 
having no recorded prescription within 90 days of admission/
index date and redemption of at least one prescription within 
91–180 days before this date. Former users had no recorded 
prescription within 180 days of their admission/index date 
and had ﬁ  lled at least one prescription within 181–365 days 
prior to this date. Nonusers had no recorded prescription for 
any antipsychotic drugs within 365 days of their admission/
index date.
The prescription databases provided information 
on current use of statins, low dose acetylsalicylic acid, 
postmenopausal hormone replacement therapy and vitamin K 
antagonists, which might affect the risk of VTE.14,19,20 As well, 
we retrieved data regarding “ever used” of oral hypoglycemic 
agents and insulin, as markers of diabetes mellitus.Clinical Epidemiology 2009:1 21
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Using conditional logistic regression analysis, we 
computed relative risk estimates (odds ratios) with 95% 
conﬁ  dence intervals, adjusting for discharge diagnoses of 
myocardial infarction, stroke, COPD, peripheral athero-
sclerosis in the legs, heart failure, diabetes and current use 
of statins, low dose acetylsalicylic acid, postmenopausal 
hormone replacement therapy and vitamin K antagonists. 
We also performed analyses stratifying cases and controls 
by sex since there is a known increased risk of VTE in users 
of oral contraceptives.14 We could not capture history of oral 
contraceptive use, since their purchase is not reimbursed by 
Denmark’s national health care system and hence not regis-
tered in the prescription databases. Since risk set sampling 
controls were used, the odds ratios are unbiased estimates 
of the corresponding rate ratios. P-values   0.05 were con-
sidered statistically signiﬁ  cant.
Results
During the study period we matched 5,999 patients with 
VTE with 59,990 population controls. Among cases, venous 
thrombosis was diagnosed in 64% (n = 3,823) and pulmonary 
embolism in the remaining 36% (n = 2,176). Characteristics 
of cases and controls are presented in Table 1. Compared 
with controls, cases had, as expected, a higher prevalence 
of previous hospitalization for surgery, trauma or fracture, 
pregnancy and cancer. Persons with this medical history 
were excluded in a second analysis restricted to 3,471 cases 
of primary, idiopathic, VTE and 34,608 population controls. 
In this analysis 67% (n = 2,310) of cases had a diagnosis 
of venous thrombosis and 33% (n = 1,161) of cases had a 
diagnosis of pulmonary embolism.
As shown in Table 2, current users of any antipsychotic 
drug had an increased risk of VTE compared with nonusers 
(adjusted relative risk [ARR]: 1.99, 95% conﬁ  dence interval 
[CI]: 1.69–2.34). An increased risk of VTE compared 
with nonusers was also observed among subgroups of 
antipsychotic drug users: current users of low-potency ﬁ  rst-
generation antipsychotics (ARR: 2.11, 95% CI: 1.51–2.95), 
current users of high-potency ﬁ  rst-generation antipsychotics 
(ARR: 1.82, 95% CI: 1.46–2.27); and current users of second-
generation antipsychotics (ARR: 2.47; 95% CI: 1.87–3.28). 
An increased risk, although not signiﬁ  cant, compared to 
nonusers was observed for former users of any antipsychotic 
drugs (ARR: 1.54; 95% CI: 0.99–2.40, p-value: 0.056) and for 
the following subgroups: former users of second-generation 
antipsychotics (ARR: 1.36; 95% CI: 0.48–3.88) and former 
users of high-potency ﬁ  rst-generation antipsychotics (ARR: 
1.73; 95% CI: 1.06–2.85). Similar relative risks were 
observed in a supplemental analysis that excluded cases and 
controls with major risk factors for VTE (Table 2).
Former users of ﬁ  rst-generation antipsychotic drugs 
might be current users of second-generation antipsychotic 
drugs, thus explaining the increased risk of VTE in these 
patients. Therefore, we controlled for current use of a 
second-generation drug in separate post hoc analyses of 
VTE risk in users of ﬁ  rst-generation drugs. These analy-
ses yielded relative risks similar to those obtained in the 
previous analyses for former users of low-potency ﬁ  rst-
generation antipsychotics (ARR: 0.92, 95% CI: 0.36–2.34) 
and for former users of high-potency ﬁ  rst-generation anti-
psychotic drugs (ARR: 1.54, 95% CI: 0.94–2.54). After 
stratifying by sex, similar risk estimates of VTE were found 
in female and male current users of any antipsychotic drug 
(ARR: 2.09, 95% CI: 1.71–2.55 and 1.82, 95% CI 1.37–2.42, 
respectively) while the risk estimates for former users 
of antipsychotics were elevated in females (ARR: 1.85, 
95% CI: 1.11–3.09), but not in males (ARR: 0.98, 95% 
CI: 0.40–2.39). Similar relative risks were observed in a 
supplemental analysis that excluded cases and controls with 
major risk factors for VTE.
Discussion
In this large population-based nested case-control study, we 
observed a 2-fold increased risk of VTE in patients currently 
prescribed antipsychotics, compared with nonusers. Although 
inconclusive, some previous studies suggest an association 
between use of antipsychotics and VTE.3–12 However, there 
is an inconsistency between the studies whether the increases 
risk is associated with first-generation antipsychotics, 
second-generation antipsychotics or both. The hypothesized 
association between ﬁ  rst-generation antipsychotic drugs and 
VTE is based primarily on one case-control study3 where 
the risk of VTE in patients using second-generation drugs 
could not be evaluated. The suggested association between 
second-generation antipsychotics and VTE is primarily sup-
ported by a cohort study4 where no increased risk of VTE 
in users of ﬁ  rst-generation antipsychotics was observed. 
Moreover, no association with VTE was found in a cohort 
of patients treated with any antipsychotic drug, except for 
patients receiving haloperidol, compared to users of thyroid 
hormones.12 In this study we found an increased risk of VTE 
in current users of low-potency ﬁ  rst-generation, high-potency 
ﬁ  rst-generation and second-generation antipsychotic drug 
compared to nonusers.
We also found a 1.5-fold increased risk of VTE in 
former users of any antipsychotic drug compared to never Clinical Epidemiology 2009:1 22
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users. Previously, the risk for VTE among former users 
of antipsychotic drugs has only been investigated in three 
studies. In two of these studies3,5 the risk of VTE in current 
users of antipsychotic drugs was compared with that of 
former users. In one study6 estimating the risk of VTE in 
formers users of antipsychotic drugs compared to nonusers, 
where a 5-fold increased, although not signiﬁ  cant (95% CI, 
0.6–46), risk for VTE was found.
Table 1 Characteristics of cases with venous thromboembolism (VTE) and population controls
All VTE cases and controls Cases with idiopathic 
VTE and controls
Variable Cases No. (%) 
N = 5,999
Controls No. (%) 
N = 59,990
Cases No. (%) 
N = 3,471
Controls No. (%) 
N = 34,608
Age, y
   55 1,349 (22.5%) 13,490 (22.5%) 886 (25.5%) 8,859 (25.6%)
  55–70 1,799 (30.0%) 17,990 (30.0%) 1,011 (29.1%) 10,108 (29.2%)
   70 2,851 (47.5%) 28,510 (47.5%) 1,574 (45.4%) 15,641 (45.2%)
Sex
  Females 3,291 (54.9%) 32,910 (54.9%) 1,858 (53.5%) 18,525 (53.5%)
  Males 2,708 (45.1%) 27,080 (45.1%) 1,613 (46.5%) 16,083 (46.5%)
Any antipsychotics
 Current  usersa 221 (3.7%) 1,128 (1.9%) 125 (3.6%) 675 (2.0%)
 Recent  usersb 33 (0.55%) 188 (0.31%) 15 (0.43%) 100 (0.29%)
 Former  usersc 27 (0.45%) 173 (0.29%) 18 (0.52%) 103 (0.30%)
Low-potency antipsychotics
 Current  usersa 51 (0.85%) 224 (0.37%) 31 (0.90%) 131 (0.38%)
 Recent  usersb 5 (0.083%) 30 (0.050%) 2 (0.058%) 15 (0.043%)
 Former  usersc 6 (0.10%) 53 (0.088%) 4 (0.12%) 31 (0.090%)
High-potency antipsychotics
 Current  usersa 116 (1.9%) 648 (1.1%) 67 (1.9%) 399 (1.2%)
 Recent  usersb 29 (0.48%) 141 (0.24%) 12 (0.35%) 85 (0.25%)
 Former  usersc 22 (0.37%) 117 (0.20%) 13 (0.38%) 68 (0.20%)
Second-generation antipsychotics
 Current  usersa 75 (1.3%) 315 (0.53%) 42 (1.2%) 183 (0.53%)
 Recent  usersb 10 (0.17%) 32 (0.053%) 6 (0.17%) 12 (0.035%)
 Former  usersc 4 (0.067%) 46 (0.077%) 4 (0.12%) 33 (0.095%)
Currenta use of statins 267 (4.5%) 2,689 (4.5%) 138 (4.0%) 1,404 (4.1%)
Currenta use of low dose acetylsalicylic acid 506 (8.4%) 4,667 (7.8%) 284 (8.2%) 2,475 (7.2%)
Current use of HRT 187 (3.1%) 1,908 (3.2%) 88 (2.5%) 962 (2.8%)
Current use of vitamin K antagonists 161 (2.7%) 1,098 (1.8%) 79 (2.3%) 568 (1.6%)
Myocardial infarction 403 (6.7%) 2,879 (4.8%) 221 (6.4%) 1,593 (4.6%)
Stroke 434 (7.2%) 2,967(5.0%) 230 (6.6%) 1,534 (4.4%)
COPD 506 (8.4%) 1,442 (2.4%) 293 (8.4%) 731 (2.1%)
Lower limb atherosclerosis 223 (3.7%) 1,047 (1.8%) 96 (2.8%) 513 (1.5%)
Heart failure 413 (6.9%) 2,226 (3.7%) 216 (6.2%) 1,157 (3.3%)
Diabetes mellitus 459 (7.7%) 3,270 (5.5%) 268 (7.7%) 1,700 (4.9%)
Surgeryd 1,709 (28.5%) 2,225 (3.7%) – –
Trauma or fractured 476 (7.9%) 1,078 (1.8%) – –
Pregnancyd 44 (0.7%) 121 (0.2%) – –
Cancere 1,183 (19.7%) 4,919 (8.2) – –
Notes: aWithin 90 days before hospital admission/index date; bWithin 91–180 days before hospital admission/index date; cWithin 181–365 days before hospital admission/index 
date; dWithin three months before hospital admission/index date; ePre-existing cancer or a cancer diagnosis within three months after hospital admission/index date.
Abbreviations: COPD, chronic obstructive pulmonary disease; HRT, hormone replacement therapy;    VTE, venous thromboembolism.Clinical Epidemiology 2009:1 23
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In our study, when study subjects were stratiﬁ  ed by sex, the 
increased risk of VTE remained only in female former users 
of any antipsychotic drugs. Since there is no known increased 
risk of VTE in females per se14 this ﬁ  nding might be explained 
by use of drugs containing female hormones, a well known 
risk factor for VTE.14 About 4% of the females in the study 
population was estimated to use oral contraceptives based on 
a reported use of oral contraceptives in 33% of Danish women 
aged 15–44 years.21 In our study, use of hormone replacement 
therapy was controlled for, but we could not control for the 
use of oral contraceptives since their costs are not reimbursed 
by the national health care system and information on ﬁ  lled 
prescriptions is not recorded in the prescription databases.13
The main strengths of this study include its population-
based design and access to prospectively recorded data on 
outcomes, possible confounding factors and drug exposure. 
A number of potential weaknesses deserve discussion. Medi-
cal records vary in quality and discharge diagnoses may not 
be entirely correct. While approximately 20% of patients 
listed in hospital discharge registries with VTE may not fulﬁ  ll 
the criteria for the disease,22 these discrepancies probably do 
not differ by drug exposure.
Although we adjusted for a wide range of possible 
confounding factors, our results may still be confounded 
by uncontrolled factors like smoking, diet, obesity and 
schizophrenic behavior. The higher smoking rate among 
psychiatric patients, compared with the general population, 
and the greater number of cigarettes consumed by these 
patients are potential confounders,2,23 since smoking and 
chronic obstructive pulmonary disease, a smoking-related 
disease, are thought to increase the risk of VTE.16,24 While 
we were not able to control for smoking, we did control for 
COPD. Moreover, we controlled for the use of some drugs 
that might affect the risk of VTE, it was not possible to control 
for drugs that are sold over the counter or drugs that are not 
reimbursed by the national health care system.
Other limitations include lack of data on compliance 
and duration of actual use of the prescribed drugs. The 
categorization of current, recent and former use thus may 
not reﬂ  ect actual use. This might explain the increased risk 
for VTE found among recent users of second-generation 
antipsychotic drugs compared to nonusers. Study find-
ings may also be inﬂ  uenced by the fact that antipsychotic 
drugs are used to treat a wide range of disorders, including 
Table 2 Crude and adjusted relative risk estimates (odds ratios) for venous thromboembolism by antipsychotic drug use compared 
with nonuse
All cases and controls Cases with idiopathic VTE and controls
Variable Unadjusted relative 
risk (95% CI)
Adjusted relative 
riska (95% CI)
Unadjusted relative 
risk (95% CI)
Adjusted relative 
riskb (95% CI)
Any antipsychotics
Current usersc 2.01 (1.73–2.33) 1.99 (1.69–2.34) 1.90 (1.56–2.31) 1.87 (1.53–2.28)
Recent usersd 1.76 (1.22–2.55) 1.53 (1.02–2.30) 1.50 (0.87–2.59) 1.44 (0.83–2.50)
Former userse 1.56 (1.04–2.35) 1.54 (0.99–2.40) 1.75 (1.06–2.89) 1.68 (1.00–2.83)
Low-potency antipsychotics
Current usersc 2.29 (1.69–3.11) 2.11 (1.51–2.95) 2.38 (1.61–3.54) 2.14 (1.43–3.20)
Recent usersd 1.67 (0.65–4.31) 1.17 (0.42–3.32) 1.33 (0.30–5.79) 0.93 (0.20–4.23)
Former userse 1.13 (0.49–2.63) 0.99 (0.39–2.54) 1.29 (0.46–3.66) 1.08 (0.37–3.17)
High-potency antipsychotics
Current usersc 1.82 (1.49–2.22) 1.82 (1.46–2.27) 1.70 (1.31–2.21) 1.71 (1.31–2.23)
Recent usersd 2.07 (1.38–3.09) 1.72 (1.10–2.70) 1.42 (0.77–2.60) 1.44 (0.78–2.65)
Former userse 1.89 (1.19–2.98) 1.73 (1.06–2.85) 1.91 (1.05–3.47) 1.81 (0.98–3.34)
Second-generation antipsychotics
Current usersc 2.41 (1.87–3.11) 2.47 (1.87–3.28) 2.33 (1.66–3.27) 2.32 (1.64–3.28)
Recent usersd 3.13 (1.54–6.36) 3.35 (1.56–7.19) 4.98 (1.87–13.26) 4.44 (1.62–12.20)
Former userse 0.87 (0.31–2.42) 1.36 (0.48–3.88) 1.21 (0.43–3.42) 1.34 (0.47–3.81)
Notes: aAdjusted for current use of statins, acetylsalicylic acid, hormone replacement therapy and Vitamin K antagonists and discharge diagnoses of stroke, chronic obstructive 
pulmonary disease, myocardial infarction, atherosclerosis, heart failure, diabetes, cancer, surgery, trauma or fracture, and pregnancy; bAdjusted for current use of statins, ace-
tylsalicylic acid, hormone replacement therapy and Vitamin K antagonists and discharge diagnoses of stroke, chronic obstructive pulmonary disease, myocardial infarction, 
atherosclerosis, heart failure, and diabetes; cWithin 90 days before hospital admission/index date; dWithin 91–180 days before hospital admission/index date; eWithin 181–365 
days before hospital admission/index date.
Abbreviations: CI, conﬁ  dence interval;    VTE, venous thromboembolism.Clinical Epidemiology 2009:1 24
Jönsson et al
psychoses, anxiety and mood disorders, behavioral disorders 
and dementia.25 Among all users of antipsychotic drugs, 48% 
were above 71 years of age. This suggests that the drugs 
are used for indications other than schizophrenia, at least in 
the elderly group. Unfortunately, we were not able to include 
information about the indication for practical reasons.
Several factors related to treatment or the underlying 
disease have been proposed as mechanisms for the increased 
risk of VTE among patients taking antipsychotic drugs.26 
First, all situations involving immobilization increase VTE 
risk.14 Psychotic patients may be immobilized due to sedation, 
a common adverse effect of many antipsychotic drugs, 
especially first-generation low-potency antipsychotics27 
and clozapine.28 Patients diagnosed with severe psychotic 
conditions may also require immobilization through sedation 
or mechanical restraint. Second, obesity, a risk factor found 
in schizophrenic patients with or without treatment with 
antipsychotic drugs, is associated with an increased risk 
of VTE.29 Clinically signiﬁ  cant weight gain is more com-
mon among patients with schizophrenia than in the general 
population and treatment with antipsychotic drugs may also 
induce weight gain.30 The increased risk of VTE thus might be 
explained by immobilization and obesity, induced by use of 
antipsychotic drugs. However, smoking and nondrug-related 
obesity could still explain the associations.
As well, antipsychotic drug treatment has been associated 
with enhanced platelet aggregation,26 and elevated levels 
of prolactin correlated with platelet activation have been 
observed.31 Clozapine has been associated with platelet 
adhesion and aggregation in vitro.32 Raised levels of antiphos-
pholipid antibodies, including lupus anticoagulantia and 
anticardiolipin antibodies, have been observed in patients 
treated with antipsychotic drugs26 and have been associated 
with increased VTE risk.14 Moderate homocysteinameia 
(15–100 μM), associated with a 2–3-fold increased risk of 
VTE,14,33 has been observed in patients with schizophrenia.34 
The mechanism by which high homocysteine levels increase 
the risk of VTE is unknown.14
In conclusion, our study found that users of antipsychotic 
drugs have an increased risk of VTE, compared with nonus-
ers. The observed increased risk might be due to the treat-
ment itself, to lifestyle factors, to the underlying disease or 
to residual confounding.
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Appendix: ICD and ATC codes
Venous thromboembolism: ICD-8 451.00, 450.99 ICD-10 
I801–03, I26
Cancer: ICD-8 140–209, ICD-10 C00–C99
Pregnancy or delivery: ICD-8 630–680, ICD-10 O00–O99
Fractures or trauma: ICD-8 800–999, ICD-10 S00–T14
Stroke: ICD-8 431–435, ICD-10 I61, I63, I64, I65, I66
Chronic obstructive disease: ICD-8 491–492, ICD-10 
J42–J44
Myocardial infarction: ICD-8 410, ICD-10 I21
Atherosclerosis extremitas inferioris: ICD-8 44020, ICD-10 
I702
Heart failure: ICD-8 42709, 42710, 42711, ICD-10 I50
Diabetes: ICD-8 249, 250, ICD-10 E10, E11
Antidiabetics: ATC codes A10A, A10B
Statins: ATC code C10AA
Low dose acetylsalicylic acid: ATC codes B01AC06
Postmenopausal hormone replacement therapy: ATC code 
G03C
Vitamin K antagonists: ATC codes B01AA03, B01AA04
Low-potency ﬁ  rst-generation antipsychotics: ATC codes 
N05AD03, N05AD05, N05AA01, N05AF03, N05AC02, 
N05AA03
High-potency ﬁ  rst-generation antipsychotics: ATC codes 
N05AF05, N05AB03, N05AC01, N05AD01, N05AF01, 
N05AG02, N05AB02, N05AG03
Second-generation antipsychotics: ATC codes N05AH02, 
N05AL01, N05AX08, N05AE03, N05AH04, N05AL05, 
N05AE04, N05AH03
Any antipsychotics: ATC codes N05AD03, N05AD05, 
N05AA01, N05AF03, N05AC02, N05AA03, N05AF05, 
N05AB03, N05AC01, N05AD01, N05AF01, N05AG02, 
N05AB02, N05AG03, N05AH02, N05AL01, N05AX08, 
N05AE03, N05AH04, N05AL05, N05AE04, N05AH03